Progenics Pharmaceuticals Reports Fourth Quarter and Full-Year 2015 Financial and Business Results

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) today announced financial and business results for the fourth quarter and full-year 2015.

According to the news:

• RELISTOR^® Net Sales Increased to $23.0 Million for the Fourth Quarter
• Oral RELISTOR Remains On-track for April 19, 2016 PDUFA
• Subcutaneous RELISTOR Approved in Europe for All Opioid-Induced Constipation
• AZEDRA^® Ultra-Orphan Cancer Therapeutic Receives FDA Breakthrough Designation
• AZEDRA Completes Enrollment of 68 Patients in Pivotal Trial and Topline Results Expected Between December 2016 and March 2017
• Initiated Pivotal Phase 3 Study of 1404, PSMA-Targeted SPECT/CT Imaging Agent
• Clinical Studies Planned for PyL PSMA-Targeted PET/CT Imaging Agent Licensed from Johns Hopkins University
• Acquired EXINI Diagnostics AB, a Swedish Developer of Artificial Intelligence-Based Image Analysis Tools to Enhance Our Prostate Cancer Imaging Agents
• Phase 1 Study of 1095, PSMA-Targeted Therapeutic for Metastatic Prostate Cancer, Planned at Memorial Sloan Kettering

Mark Baker, CEO of Progenics commented:
Over the past year, we have achieved significant progress across all three areas of our business – our partnered OIC therapy, RELISTOR, our ultra-orphan radiotherapeutic candidate, AZEDRA, and our prostate cancer pipeline. I expect 2016 to be a transformational year for our Company with a number of important milestones.  We begin the year in a strong financial position, and Oral RELISTOR, if approved, will trigger a milestone payment and sales royalties that we can use to further advance AZEDRA toward commercialization while also developing our pipeline of therapeutic and imaging agents that we believe have the potential to change how prostate cancer is diagnosed and treated.
Click here to view the full press release.